These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34449094)

  • 1. Trough polymyxin B plasma concentration is an independent risk factor for its nephrotoxicity.
    Han L; Xu FM; Zhang XS; Zhang CH; Dai Y; Zhou ZY; Wang YX; Chen F; Shi DW; Lin GY; Yu XB
    Br J Clin Pharmacol; 2022 Mar; 88(3):1202-1210. PubMed ID: 34449094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for polymyxin B-associated acute kidney injury.
    Chang K; Wang H; Zhao J; Yang X; Wu B; Sun W; Huang M; Cheng Z; Chen H; Song Y; Chen P; Chen X; Gan X; Ma W; Xing L; Wang Y; Cao B
    Int J Infect Dis; 2022 Apr; 117():37-44. PubMed ID: 35108608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study.
    Rigatto MH; Behle TF; Falci DR; Freitas T; Lopes NT; Nunes M; Costa LW; Zavascki AP
    J Antimicrob Chemother; 2015 May; 70(5):1552-7. PubMed ID: 25604744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of Acute Kidney Injury in Intermittent Versus Continuous Infusion of Polymyxin B in Hospitalized Patients.
    Alvarado Reyes Y; Cruz R; Gonzalez J; Perez Y; Wolowich WR
    Ann Pharmacother; 2019 Sep; 53(9):886-893. PubMed ID: 30971094
    [No Abstract]   [Full Text] [Related]  

  • 5. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.
    Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP
    Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy.
    Kubin CJ; Ellman TM; Phadke V; Haynes LJ; Calfee DP; Yin MT
    J Infect; 2012 Jul; 65(1):80-7. PubMed ID: 22326553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of risk factors of polymyxin B-associated acute kidney injury in intensive care unit patients with severe infection].
    Wang Y; Chen X; Guo X; Cao K; Zhu Z; Zhang B; Liang P; Yu W
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Jun; 32(6):716-720. PubMed ID: 32684219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Nephrotoxicity Associated With Nonrenally Adjusted Intravenous Polymyxin B Compared to Traditional Dosing.
    Maniara BP; Healy LE; Doan TL
    J Pharm Pract; 2020 Jun; 33(3):287-292. PubMed ID: 30253682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing the Population Pharmacokinetics of and Acute Kidney Injury Due to Polymyxin B in Chinese Patients with or without Renal Insufficiency.
    Wang P; Zhang Q; Zhu Z; Pei H; Feng M; Sun T; Yang J; Zhang X
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymyxin-B and vancomycin-associated acute kidney injury in critically ill patients.
    Soares DS; Reis ADF; Silva Junior GBD; Leite TT; Parente Filho SLA; Rocha CVO; Daher EF
    Pathog Glob Health; 2017 May; 111(3):137-142. PubMed ID: 28353411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrotoxicity Associated with Intravenous Polymyxin B Once- versus Twice-Daily Dosing Regimen.
    Okoduwa A; Ahmed N; Guo Y; Scipione MR; Papadopoulos J; Eiras DP; Dubrovskaya Y
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does Monitoring Total and Free Polymyxin B1 Plasma Concentrations Predict Polymyxin B-Induced Nephrotoxicity? A Retrospective Study in Critically Ill Patients.
    Deng Y; Gu JY; Li X; Tong H; Guo SW; Xu B; Li Y; Zhang BK; Li Y; Huang HY; Xiao GY
    Infect Dis Ther; 2022 Aug; 11(4):1591-1608. PubMed ID: 35689791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Risk factors for acute kidney injury in patients treated with polymyxin B experience from 139 cases at a tertiary university hospital in Colombia].
    Osorio J; Barreto J; Samboni CF; Cándelo LA; Álvarez LC; Benavidez S; Téllez RP; Santofimio D; Ramos JA; Gómez CA
    Rev Chilena Infectol; 2017 Feb; 34(1):7-13. PubMed ID: 28394975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use.
    Mendes CA; Cordeiro JA; Burdmann EA
    Ann Pharmacother; 2009 Dec; 43(12):1948-55. PubMed ID: 19887593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nephrotoxicity in Patients with or without Cystic Fibrosis Treated with Polymyxin B Compared to Colistin.
    Crass RL; Rutter WC; Burgess DR; Martin CA; Burgess DS
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness, nephrotoxicity, and therapeutic drug monitoring of polymyxin B in nosocomial pneumonia among critically ill patients.
    Ye Q; Wang Q; Chen Z; Chen W; Zhan Q; Wang C
    Clin Respir J; 2022 May; 16(5):402-412. PubMed ID: 35586931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An area under the concentration-time curve threshold as a predictor of efficacy and nephrotoxicity for individualizing polymyxin B dosing in patients with carbapenem-resistant gram-negative bacteria.
    Yang J; Liu S; Lu J; Sun T; Wang P; Zhang X
    Crit Care; 2022 Oct; 26(1):320. PubMed ID: 36258197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between the drug concentration of polymyxin B and polymyxin B-associated acute kidney injury in critically ill patients: A prospective study.
    Xu Y; Liang P; Liu N; Dong D; Gu Q; Wang X
    Pharmacol Res Perspect; 2022 Oct; 10(5):e01010. PubMed ID: 36206131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymyxin B and colistin-the economic burden of nephrotoxicity against multidrug resistant bacteria.
    Tuon FF; Rocha JL; Gasparetto J
    J Med Econ; 2019 Feb; 22(2):158-162. PubMed ID: 30466325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Candidates for area under the concentration-time curve (AUC)-guided dosing and risk reduction based on analyses of risk factors associated with nephrotoxicity in vancomycin-treated patients.
    Hashimoto N; Kimura T; Hamada Y; Niwa T; Hanai Y; Chuma M; Fujii S; Matsumoto K; Shigemi A; Kawamura H; Takahashi Y; Takesue Y
    J Glob Antimicrob Resist; 2021 Dec; 27():12-19. PubMed ID: 34371241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.